Pain Management

Following is a digest of pharmacogenomics journal articles pertaining to pain. The SNP•its editorial team selects articles for inclusion based on clinical relevance and scientific validity. Journal articles that are most readily applicable and relevant to practicing clinicians are selected for a SNP•its Study Summary, which discusses findings and clinical implications of a pharmacogenomics study in the context of the larger evidence base.

Article Citation & LinkTypeMonthSNP•its Study Summary
Kapil RP et al. Effects of paroxetine, a CYP2D6 inhibitor, on the pharmacokinetic properties of hydrocodone after coadministration with a single-entity, once-daily, extended-release hydrocodone tablet. Clin Ther. 2016;38:228-9.Pharmacokinetic2016-01
Baber M et al. The pharmacogenetics of opioid therapy in the management of postpartum pain: a systematic review. Pharmacogenomics. 2016;17:75-93.Systematic Review2016-01
Ruan X et al. Is it truly the answer? Personalized oxycodone dosing based on pharmacogenetic testing and the corresponding pharmacokinetics. Pain Med. 2016 Jan 11 [Epub ahead of print].Perspective2016-01
Meshkin B et al. Adding genetic testing to evidence-based guidelines to determine the safest and most effective chronic pain treatment for injured workers. Int J Biomed Sci. 2015;11:157-65.Commentary2015-12
Bell GC et al. Clinical implications of opioid pharmacogenomics in patients with cancer. Cancer Control. 2015;22:426-32.Review2015-10
Mazaleuskaya LL et al. PharmGKB summary: pathways of acetaminophen metabolism at the therapeutic versus toxic doses. Pharmacogenet Genom. 2015 Aug 25 [Epub ahead of print].PharmGKB Summary2015-08
Jimenez N et al. Personalizing pediatric pain medicine: using population-specific pharmacogenetics, genomics, and other -omics approaches to predict response. Anesth Analg. 2015;121:183–7.Review2015-07
Tadje M. Genetic variants influencing patient response opioid therapy. Oncol Nurs Forum. 2015;42:420–2.Review2015-07
Nielsen LM et al. Association between human pain-related genotypes and variability in opioid analgesia: an updated review. Pain Pract. 2015;15:580–94.Review2015-07
DePriest AZ et al. Metabolism and disposition of prescription opioids: a review. Forensic Sci Rev. 2015;27:115-45.Review2015-07
Dong H et al. Effect of the CYP2D6 gene polymorphism on postoperative analgesia of tramadol in Han nationality nephrectomy patients. Eur J Clin Pharmacol. 2015;71:681-6.Prospective Cohort2015-06
Yiannakopoulou E. Pharmacogenomics and opioid analgesics: clinical implications. Int J Genomics. 2015;2015:368979.Review2015-05
Seripa D et al. Role of CYP2D6 polymorphisms in the outcome of postoperative pain treatment. Pain Med 2015 May 19 [Epub ahead of print].Longitudinal cohort study2015-05
Wu S-B et al. Impact of CYP2D6 Polymorphisms on Postoperative Fentanyl Analgesia in Gastric Cancer Patients. Genet Test Mol Biomarkers. 2015;19:248-52.Prospective Cohort2015-04
Ren Z-Y et al. The impact of genetic variation on sensitivity to opioid analgesics in patients with postoperative pain: a systematic review and meta-analysis. Pain Physician. 2015;18:131–52.Meta-Analysis2015-03
Crews KR et al. Considerations for the utility of the CPIC guideline for CYP2D6 genotype and codeine therapy. Clin Chem. 2015;61:775-6.Letter2015-03
Manworren RCB. Multimodal pain management and the future of a personalized medicine approach to pain. AORN J. 2015;101:308–14.Review2015-03
Manworren RCB et al. Pharmacogenetic testing for analgesic adverse effects: pediatric case series. Clin J Pain. 2015 Mar 23 [Epub ahead of print].Case Series2015-03
Baber M et al. The pharmacogenetics of codeine pain relief in the postpartum period. Pharmacogenomics J. 2015 Mar 10 [Epub ahead of print].Cohort 2015-03
Orliaguet G et al. A case of respiratory depression in a child with ultrarapid CYP2D6 metabolism after tramadol. Pediatrics. 2015;135:e753-5.Case Report2015-03Case report: Tramadol-associated respiratory depression in CYP2D6 ultrarapid metabolizer
Jaja C et al. Preemptive genotyping of CYP2C8 and CYP2C9 allelic variants involved in NSAIDs metabolism for sickle cell disease pain management. Clin Transl Sci. 2015; Feb 2 [Epub ahead of print].Retrospective Cohort2015-02
Somogyi A et al. Pharmacogenetics of opioid response. Clin Pharmacol Ther. 2015;97:125–7.Review2015-02
Heintze K et al. Codeine ultra-rapid metabolizers: age appears to be a key factor in adverse effects of codeine. Drug Res (Stuttg). 2015 Jan 13 [Epub ahead of print].Review2015-01
Linares OA et al. Individualized hydrocodone therapy based on phenotype, pharmacogenetics, and pharmacokinetic dosing. Clin J Pain. 2015 Jan 23 [Epub ahead of print].PK2015-01
Clarke H et al. Genetics of chronic post-surgical pain: a crucial step toward personal pain medicine. Can J Anaesth. 2014 Dec 4 [Epub ahead of print].Review2014-12
Biesiada J et al. Genetic risk signatures of opioid-induced respiratory depression following pediatric tonsillectomy. Pharmacogenomics. 2014;15:1749–62.Prospective Clinical Trial2014-11
Nicholson WT et al. Clinical perspective on the Clinical Pharmacogenetics Implementation Consortium updated 2014 guidelines for CYP2D6 and codeine. Clin Chem. 2014 Oct 9 [Epub ahead of print].Perspective2014-10Clinical applications of CYP2D6–codeine guidelines
DeFeo K et al. How does pharmacogenetic testing alter the treatment course and patient response for chronic-pain patients in comparison with the current “trial-and-error” standard of care? J Am Assoc Nurse Pract. 2014;26:530–6.Review2014-10
Trescot AM et al. A review of the role of genetic testing in pain medicine. Pain Physician. 2014;17:425-45.Review2014-09 
Nielsen LM et al. Association Between Human Pain-Related Genotypes and Variability in Opioid Analgesia: An Updated Review. Pain Pract. 2014 Sep [Epub ahead of print].Review2014-09 
Kapur BM et al. Pharmacogenetics of chronic pain management. Clin Biochem. 2014;47:1169-87.Systematic Review2014-09 
Monte AA et al. The Effect of CYP2D6 Drug-Drug Interactions on Hydrocodone Effectiveness. Acad Emerg  Med. 2014;21:879–885.Prospective cohort study

2014-08CYP2D6 Drug Interactions and Response to Hydrocodone, Ondansetron
Gong L et al. PharmGKB summary: tramadol pathway. Pharmacogenet Genomics. 2014;24:374-80.Review2014-06 
Lam J et al. Codeine-related deaths: The role of pharmacogenetics and drug interactions. Forensic Sci Int. 2014;239C:50-6. Retrospective cohort study2014-06Drug interactions, pharmacogenetics influence codeine, morphine levels
Fudin J et al. Personalized oxycodone dosing: Using pharmacogenetic testing and clinical pharmacokinetics to reduce toxicity risk and increase effectiveness [commentary]. Pain Med. 2014;15:723-5.Editorial2014-05 
Prows CA et al. Codeine-related adverse drug reactions in children following tonsillectomy: a prospective study. Laryngoscope. 2014;124:1242-50.  Prospective cohort study2014-05 
Linares OA et al. Personalized oxycodone dosing: using pharmacogenetic testing and clinical pharmacokinetics to reduce toxicity risk and increase effectiveness. Pain Med. 2014;15:791-806.Pharmacokinetic2014-05 
Kirsh KL et al. Exploring rates of abnormal pharmacogenetic findings in a pain practice. J Pain Palliat Care Pharmacother. 2014; 28:28-32. Cross-sectional2014-03 

Tagged as: ,